| 7. Trade and other payables
|
|
|
|
|
|
|
|
|
| (US$’000) |
|
March 31,
2025 |
|
|
June 30,
2024 |
|
Trade payable |
|
$ |
433 |
|
|
$ |
1,351 |
|
Accrued consultant fees |
|
|
36 |
|
|
|
75 |
|
Accrued professional fees |
|
|
394 |
|
|
|
97 |
|
Accrued clinical development project costs |
|
|
5,234 |
|
|
|
2,504 |
|
Other payables |
|
|
157 |
|
|
|
138 |
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
6,254 |
|
|
$ |
4,165 |
|
|
|
|
|
|
|
|
|
| During the ended March 31, 2025, the Company agreed to resolve disputed trade payables and accrued clinical development project costs of $1.2 million with a vendor for $495 thousand. This settlement resulted in a gain of $764 thousand recorded in the statement of operations and other comprehensive loss under other income (expense) for the period. |